Literature DB >> 17761674

The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.

Marlène Dreux1, Bertrand Boson, Sylvie Ricard-Blum, Jennifer Molle, Dimitri Lavillette, Birke Bartosch, Eve-Isabelle Pécheur, Francois-Loïc Cosset.   

Abstract

Cell entry of hepatitis C virus (HCV) is strikingly linked to lipoproteins and their receptors. Particularly, high density lipoprotein (HDL) enhances infectivity of HCV by involving the lipid-transfer function of the scavenger receptor BI, a receptor for both HDL and HCV. Here, we demonstrate that apoC-I, an exchangeable apolipoprotein that predominantly resides in HDL, specifically enhances HCVcc and HCVpp infectivity and increases the fusion rates between viral and target membranes via a direct interaction with the HCV surface. We identify the hypervariable region 1, located at the N terminus of the HCV E2 glycoprotein, as an essential viral component that modulates apoC-I-mediated enhancement of HCV fusion properties. The affinity of apoC-I for the HCV membrane may predispose it for fusion with a target membrane via alterations of its outer phospholipid layer. Conversely, we found that excess apoC-I provided as lipoprotein-free protein induces the disruption of the HCV membrane and subsequent loss of infectivity. Furthermore, our data indicate that HDL neither interacts nor spontaneously exchanges apoC-I with HCV virions. Because apoC-I is not present in serum as a lipoprotein-free form, our results suggest that HDL-embedded apoC-I could be released from the lipoprotein particle through a fine-tuned mechanism regulated via a triple interplay between hypervariable region 1, HDL, and scavenger receptor BI, resulting in optimal apoC-I recruitment on the viral membrane. These results provide the first description of a host serum factor helping the fusion process of an enveloped virus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761674     DOI: 10.1074/jbc.M705358200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome.

Authors:  Andreas Merz; Gang Long; Marie-Sophie Hiet; Britta Brügger; Petr Chlanda; Patrice Andre; Felix Wieland; Jacomine Krijnse-Locker; Ralf Bartenschlager
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

3.  Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Authors:  Dorothea Bankwitz; Eike Steinmann; Julia Bitzegeio; Sandra Ciesek; Martina Friesland; Eva Herrmann; Mirjam B Zeisel; Thomas F Baumert; Zhen-yong Keck; Steven K H Foung; Eve-Isabelle Pécheur; Thomas Pietschmann
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 4.  Hepatitis C virus relies on lipoproteins for its life cycle.

Authors:  Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 5.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

6.  Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation.

Authors:  Urtzi Garaigorta; Francis V Chisari
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

7.  Apolipoprotein c1 association with hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Ronald E Engle; Kristina N Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.

Authors:  Takuya Matsumura; Zongyi Hu; Takanobu Kato; Marlene Dreux; Yong-Yuan Zhang; Michio Imamura; Nobuhiko Hiraga; Jean-Marc Juteau; Francois-Loic Cosset; Kazuaki Chayama; Andrew Vaillant; T Jake Liang
Journal:  Gastroenterology       Date:  2009-04-23       Impact factor: 22.682

Review 9.  Targeting host factors: a novel rationale for the management of hepatitis C virus.

Authors:  Mahmoud Aboelneen Khattab
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

10.  Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Authors:  Marlène Dreux; Viet Loan Dao Thi; Judith Fresquet; Maryse Guérin; Zélie Julia; Géraldine Verney; David Durantel; Fabien Zoulim; Dimitri Lavillette; François-Loïc Cosset; Birke Bartosch
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.